Products of 570 companies at the stands, presentations within the framework of the Forum "Pharmtechprom" and the session "The role of the technical customer in the creation of pharmaceutical industry facilities"

Session "The Role of the Technical Customer in the Creation of Pharmaceutical Industry Facilities"

As part of the second day of the Pharmtech & Ingredients business program , Primekey Group held a session on “The Role of the Technical Customer in the Creation of Pharmaceutical Industry Facilities.”

The event covered a wide range of issues related to the design, construction and commissioning of production projects in the pharmaceutical industry.

The session was devoted to these processes from the point of view of one of their main participants – the technical customer. The speakers, leading experts in the field of construction and pharmaceutical engineering, discussed the current state of the technical customer institute in Russia, problems and development prospects, the role of the technical customer at all stages of an investment and construction project, the functions of the technical customer in pre-project development and design, legal aspects of the technical customer’s activities, and also shared practical recommendations for designing pharmaceutical industry facilities.

"The creation of a pharmaceutical enterprise is a multi-stage complex work, at each level of which professionals must be involved. That is why the involvement of a competent technical customer is one of the key tools for competent project management. Experience in implementing pharmaceutical production projects from different sides and the development of an optimal design for conducting such work are important ," added the session moderator, Chairman of the Board of Directors of PRIMEKEY Group Oleg Malakhov.

Forum "Pharmtechprom"

As part of the exhibition's business program, the Pharmtechprom Forum was held on November 20 , where industry experts discussed the state of pharmaceutical production in Russia. The event was moderated by Nadezhda Romanova, Sales and Technical Support Manager at HARKE RUS LLC .

The first block of discussion was devoted to an overview of raw materials and ingredients for pharmaceutical production. The discussion of current issues was opened by a report by DSM Group CEO Sergey Shulyak on the topic "Overview of the Russian Pharmaceutical Market".

According to research, the pharmaceutical market is currently growing due to the pharmacy segment. The volume of the pharmacy segment for 9 months of 2024 showed an increase of +17%. It continues to occupy a key place in the development of the Russian pharmaceutical market.

As for the indicators for the execution of government contracts, as the speaker noted, negative dynamics are still being observed. "Almost all segments have negative dynamics in rubles, but it is worth considering that in previous years we had very high bases that were associated with COVID and other events, so we do not see high indicators for the government segment yet," commented Sergey Shulyak.

The expert also emphasized that the government procurement market continues to decline in packages due to the switch to larger packages. This is due to the redistribution into segments that cannot be discussed yet. "Speaking about the structure of hospital purchases, it can be noted that there are programs that show negative growth, there are federal programs that are increasing. At the moment, we can conclude that consumption is falling slightly," added Sergey Shulyak.

Considering the direction of purchases under the federal benefit, it was noted that under the VZN, drugs were purchased for 108% of the planned budget, despite the drop in volumes compared to last year. Also, due to a decrease in supplies under the RLO in the 3rd quarter, the total volume of the regional benefit fell. In addition, the speaker noted that, in general, the pharmaceutical market has stabilized at the moment. "The market is stable and is affected by seasonal factors, as they were before 2020. Both drugs (+17%) and parapharmaceutical products (+16%), both areas are growing almost equally," said Sergey Shulyak.

In the packaging segment, the market is not growing dynamically. "The fact is that consumer preferences are changing, the priority is changing towards more expensive, worthy drugs. Because of this, the consumer base is not growing, the level of consumption remains at the same level," the expert explained, adding that 3.2 billion packages were sold in 9 months (+0.2%).

Also, according to the speaker, the market in physical terms is growing due to "large" packages, as consumers choose such packages due to the benefit and convenience. And the next thing the speaker noted is that localized drugs occupy almost 69% of the market in packages. In the pharmacy market, the share of localized drugs is growing. In the state segment, in value terms, the share of localized drugs is decreasing, the share in packages is growing.

Summing up, Sergey Shulyak emphasized that now in 2024–2025, the pharmaceutical market is expected to grow due to the commercial segment; growth is predicted to be in the range of up to 10% next year.

The next speaker, Pavel Pavlov , Head of the Laboratory of Organic Synthesis of the Scientific Center "MTX" of the GC "ECOS-1" , spoke about the capabilities of the laboratories of the GC "ECOS-1" in the context of a review of chemical raw materials, solvents and reagents for pharmaceutical production

The expert noted the main areas of activity of the scientific center, which is part of the ECOS-1 Group of Companies, which could be useful for the development of the pharmaceutical market:

• Conducting comprehensive scientific research on the creation of chemical substances and innovative materials;
• Development of technologies for obtaining products with specified parameters of composition and purity;
• Development of design documentation (letters "A", "O1", "O");
• Testing and implementation of technologies for the production and industrial production of chemical products;
• Product quality control and analytical support;
• Modeling and determination of chemical properties of reagents.

Pavel Pavlov also noted that the scientific center is equipped with modern analytical and synthetic equipment for the synthesis, isolation and purification of both inorganic and organic compounds. Thanks to this, such methods of chemical research as chemical, spectral, elemental analysis, chromatography can be used.

The research center also has import-substituting projects for high-tech industries, such as the development and production of high-purity solvents (isopropanol, solvent) for microelectronic production.

The head of the scientific information and research center of Artlife LLC, Roman Marchenko , told the audience about the features of biotechnological ingredients for dietary supplements and cosmetics .

His presentation provided information on the development of the biotechnological direction of the Artlife company, and also demonstrated the main areas of biotechnological production - probiotics, metabiotics, fermented products, higher fungi.

During his presentation, Roman Marchenko noted that predominantly bacterial lysates and fungal mycelium with metabolites can be used in cosmetic products such as:

• Nourishing and protective creams
• Masks, rinses, sprays for oily scalp
• Hygienic napkins
• Toothpastes that promote non-specific prevention of respiratory diseases
• Anti-aging therapy products
• Intimate hygiene products
• Hair growth stimulating products
• Hair care products
• Wound healing and anti-inflammatory products

The second session of the Pharmtechprom Forum was devoted to the topic of "Packaging materials and equipment for pharmaceutical production". The moderator of the second block of the event was leading expert in packaging procurement Sergey Popov.

The CEO of JSC PROMIS Evgeny Slinyakov spoke about current trends in the pharmaceutical packaging market. The expert shared statistics on the current situation and forecasts.

According to the speaker, approximately 6 billion packages of medicines were sold in 2023. At the moment, the forecast for 2024 is based on the fact that 6344.15 billion packages will be sold. Thus, the growth will be +5%. "The growth occurred primarily due to the fact that Russian manufacturers mastered and "import substituted" those manufacturers that left the market. The second reason is related to the fact that in 2024 there was a significant increase in exports," added Evgeny Slinyakov.

The expert also noted that, thanks to the PHARMA-2030 strategy, which was approved by the order of the Government of the Russian Federation dated June 7, 2023 No. 1495-r, the market should achieve the following results:

// An increase in the share of medicines produced in the Russian Federation from 36.6% to 42.7% (in monetary terms) and from 61.8% to 66.6% (in kind), taking into account the growth of the medicines market to 3.757 trillion rubles and 5.38 billion packages.
// An increase in the share of medicinal products included in the SZLS, produced using a full cycle, from 67.44% to 80%.
// Export volume increased from USD 1.28 billion to USD 3.4 billion.

We look forward to seeing you at Pharmtech & Ingredients 2024 on November 21 and 22!